Showing 221-230 of 355 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2027 | $960,000.00 |
| Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. | The Regents of the University of California, San Francisco | Danielle Hessler | Improving Lives | 01-August-2023 to 14-September-2027 | $1,743,010.00 |
| Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation | The Regents of the University of California, San Francisco | Bhushan Kharbikar | Cures | 01-March-2024 to 28-February-2027 | $215,604.64 |
| Targeting Complement-Driven Antigen Presentation in Tertiary Lymphoid Structures to Prevent Type 1 Diabetes | The Regents of the University of California, San Francisco | Anil Bhushan | Cures | 01-September-2026 to 31-August-2028 | $498,142.00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1,808,522.70 |
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643,550.00 |
| Quality, Equity & Outcomes Program | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-September-2026 to 31-August-2028 | $1,400,000.00 |
| Engineered Nanoparticles for Beta Cell-Targeted Therapeutics | The University of Chicago | Raghavendra Mirmira | Cures | 01-April-2023 to 31-August-2026 | $897,822.00 |
| Expanding the Therapeutic and Targeting Capacity of Lipid Nanoparticles for Beta-Cell Protection | The University of Chicago | Raghavendra Mirmira | Cures | 01-September-2026 to 31-August-2028 | $471,201.00 |
| A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation | The University of Chicago | Piotr Witkowski | Cures | 01-February-2024 to 31-October-2026 | $250,000.00 |